Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in Br J Dermatol

Retrieve available abstracts of 268 articles:
HTML format



Single Articles


    July 2021
  1. STOER NC, Botteri E, Busund M, Ghiasvand R, et al
    Menopausal hormone therapy and risk of melanoma: a population-based cohort study.
    Br J Dermatol. 2021 Jul 13. doi: 10.1111/bjd.20640.
    PubMed     Abstract available


  2. SCATOLINI M, Patel A, Grosso E, Mello-Grand M, et al
    GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma.
    Br J Dermatol. 2021 Jul 8. doi: 10.1111/bjd.20629.
    PubMed     Abstract available


  3. VITALI F, Colucci R, Di Paola M, Pindo M, et al
    Early melanoma invasivity correlates with gut fungal and bacterial profiles.
    Br J Dermatol. 2021 Jul 6. doi: 10.1111/bjd.20626.
    PubMed     Abstract available


    June 2021
  4. ALTAYEB A, Dawood S, Atwan A, Mills C, et al
    Teledermoscopy: A Helpful Detection Tool for Amelanotic and Hypomelanotic Melanoma.
    Br J Dermatol. 2021 Jun 29. doi: 10.1111/bjd.20609.
    PubMed     Abstract available


  5. HARGADON KM
    The Role of Interferons in Melanoma Resistance to Immune Checkpoint Blockade: Mechanisms of Escape and Therapeutic Implications.
    Br J Dermatol. 2021 Jun 29. doi: 10.1111/bjd.20608.
    PubMed     Abstract available


  6. WIGGINS J, Polsky D
    Melanoma origins: data from early-stage tumours supports de novo and naevus-associated melanomas as distinct subtypes.
    Br J Dermatol. 2021 Jun 11. doi: 10.1111/bjd.20396.
    PubMed    


  7. GUHAN S, Klebanov N, Tsao H
    Melanoma genomics: a state-of-the-art review of practical clinical applications.
    Br J Dermatol. 2021 Jun 6. doi: 10.1111/bjd.20421.
    PubMed     Abstract available


  8. GAO JM, Garioch JJ, Fadhil M, Tan E, et al
    Planning slow Mohs excision margins for lentigo maligna: a retrospective nonrandomized cohort study comparing reflectance confocal microscopy margin mapping vs. visual inspection with dermoscopy.
    Br J Dermatol. 2021;184:1182-1183.
    PubMed    


    May 2021
  9. YEH I, Bastian BC
    Melanoma pathology: new approaches and classification.
    Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20427.
    PubMed     Abstract available


  10. MAHAMAT-SALEH Y
    Is consumption of citrus associated with a higher risk of melanoma?
    Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20408.
    PubMed    


  11. CLAESON M, Baade P, Marchetti M, Brown S, et al
    Comparative performance of predictors of death from thin (
    Br J Dermatol. 2021 May 12. doi: 10.1111/bjd.20480.
    PubMed     Abstract available


    April 2021
  12. DOUSSET L, Martins C, Jacquemin C, Amico S, et al
    Complete response in a patient with advanced melanoma following anti-PD-1 therapy is associated with high frequency of melanoma-infiltrating CXCR3(+) resident memory CD8(+) T cells and multiple chemokine pathways.
    Br J Dermatol. 2021 Apr 24. doi: 10.1111/bjd.20405.
    PubMed     Abstract available


  13. DESSINIOTI C, Geller AC, Whiteman DC, Garbe C, et al
    Not all melanomas are created equal: A review and call for more research into nodular melanoma.
    Br J Dermatol. 2021 Apr 16. doi: 10.1111/bjd.20388.
    PubMed     Abstract available


  14. KITTLER H
    Total body photography for secondary prevention of melanoma.
    Br J Dermatol. 2021 Apr 6. doi: 10.1111/bjd.20058.
    PubMed    


  15. AGRAWAL R, Tso S, Eltigani EA, Busam KJ, et al
    PRAME immunohistochemistry as an adjunct in the diagnosis of paucicellular lentigo maligna in a young man.
    Br J Dermatol. 2021;184:e122.
    PubMed    


    March 2021
  16. MARLEY AR, Li M, Champion VL, Song Y, et al
    The Association between Citrus Consumption and Melanoma Risk in the UK Biobank.
    Br J Dermatol. 2021 Mar 30. doi: 10.1111/bjd.19896.
    PubMed     Abstract available


  17. GHIASVAND R
    Divergent pathways for melanoma: what is the role of genetics?
    Br J Dermatol. 2021 Mar 25. doi: 10.1111/bjd.19887.
    PubMed    


  18. PEREZ M, Chakraborty A, Lau LS, Mohammed NBB, et al
    Melanoma-associated glycosyltransferase GCNT2 as an emerging biomarker and therapeutic target.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19891.
    PubMed     Abstract available


  19. EL SHAROUNI MA, Varey AHR, Witkamp AJ, Ahmed T, et al
    Predicting sentinel node positivity in melanoma patients: external validation of a risk-prediction calculator (the MIA nomogram) using a large European population-based patient cohort.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19895.
    PubMed     Abstract available


    February 2021
  20. WOLNER ZJ, Flowers NI, Yushak ML, Chen SC, et al
    Exploring the melanoma survivorship experience: a qualitative study.
    Br J Dermatol. 2021 Feb 5. doi: 10.1111/bjd.19868.
    PubMed     Abstract available


    January 2021
  21. DESSINIOTI C, Geller AC, Stergiopoulou A, Dimou N, et al
    A multicenter study of nevus-associated melanoma versus de novo melanoma, tumor thickness and body site differences.
    Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19819.
    PubMed     Abstract available


  22. NAGORE E, Martinez-Garcia MA, Gomez-Olivas JD, Manrique-Silva E, et al
    Relationship between type 2 diabetes mellitus and markers of cutaneous melanoma aggressiveness: An observational multi-centric study in 443 patients with melanoma.
    Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19813.
    PubMed     Abstract available


  23. GAULT A, Anderson AE, Plummer R, Stewart C, et al
    Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
    Br J Dermatol. 2021 Jan 4. doi: 10.1111/bjd.19750.
    PubMed     Abstract available


    December 2020
  24. TOLAND AE
    The influence of sex, age and sunlight exposure on mutational processes in melanoma.
    Br J Dermatol. 2020 Dec 28. doi: 10.1111/bjd.19336.
    PubMed    


  25. JI-XU A, Dinnes J, Matin RN
    Total Body Photography for the Diagnosis of Cutaneous Melanoma in Adults: A Systematic Review and Meta-Analysis.
    Br J Dermatol. 2020 Dec 28. doi: 10.1111/bjd.19759.
    PubMed     Abstract available


  26. VUONG K, Armstrong BK, Espinoza D, Hopper JL, et al
    An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study.
    Br J Dermatol. 2020 Dec 3. doi: 10.1111/bjd.19706.
    PubMed     Abstract available


  27. LASKAR R, Ferreiro-Iglesias A, Bishop DT, Iles MM, et al
    Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity.
    Br J Dermatol. 2020 Dec 3. doi: 10.1111/bjd.19705.
    PubMed     Abstract available


    November 2020
  28. NAKAMURA M, Obayashi M, Yoshimitsu M, Kato H, et al
    Comparative whole-exome sequencing of an ultra-late recurrent malignant melanoma.
    Br J Dermatol. 2020 Nov 18. doi: 10.1111/bjd.19680.
    PubMed     Abstract available


    October 2020
  29. CHARVET E, Kramkimel N, Chaplain L, Gantzer A, et al
    Second primary cutaneous melanoma in patients with advanced melanoma treated with anti-PD-1 monoclonal antibodies.
    Br J Dermatol. 2020 Oct 24. doi: 10.1111/bjd.19629.
    PubMed     Abstract available


  30. GHIASVAND R, Khosrotehrani K, Hughes MCB, von Schuckmann LA, et al
    Patient age and risk of recurrence of primary melanoma at high risk of spread.
    Br J Dermatol. 2020 Oct 14. doi: 10.1111/bjd.19601.
    PubMed     Abstract available


  31. MINIOTTI M, Ribero S, Leombruni P
    Targeting fear of recurrence: the advantages of assessing psychosocial attributes and psychological dispositions.
    Br J Dermatol. 2020;183:789-790.
    PubMed    


  32. HAUGAARD JH, Egeberg A
    Do we need to fear methotrexate?
    Br J Dermatol. 2020;183:608-609.
    PubMed    


    September 2020
  33. MIRZA FN, Yumeen S, Walter FM
    The Epidemiology of Malignant Melanoma, Squamous Cell Carcinoma, and Basal Cell Carcinoma in the United Kingdom from 2004-2014: A Population-Based Cohort Analysis using the Clinical Practice Research Datalink.
    Br J Dermatol. 2020 Sep 6. doi: 10.1111/bjd.19542.
    PubMed     Abstract available


  34. ELSARAFY S, Tobiss H, Veitch D, Bhuchar M, et al
    Ruptured hair follicles of the scalp mimicking malignant melanoma.
    Br J Dermatol. 2020 Sep 6. doi: 10.1111/bjd.19476.
    PubMed    


  35. BLANKENSTEIN SA, van Akkooi ACJ
    Broadening indications for neoadjuvant immunotherapy.
    Br J Dermatol. 2020;183:421-422.
    PubMed    


    August 2020
  36. OLSEN CM, Pandeya N, Dusingize JC, Thompson BS, et al
    Reproductive factors, hormone use and melanoma risk: an Australian prospective cohort study.
    Br J Dermatol. 2020 Aug 27. doi: 10.1111/bjd.19498.
    PubMed     Abstract available


  37. MULDER EEAP, Dwarkasing JT, Tempel D, van A, et al
    Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) model for sentinel lymph node metastasis in primary cutaneous melanoma.
    Br J Dermatol. 2020 Aug 26. doi: 10.1111/bjd.19499.
    PubMed     Abstract available


  38. KIM HS, Ahn HS
    Response to 'The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea': reply from authors.
    Br J Dermatol. 2020 Aug 7. doi: 10.1111/bjd.19465.
    PubMed     Abstract available


  39. NAPOLITANO M, Caiazzo G, Fabbrocini G, Balato A, et al
    Increased expression of IL-23A in lesional skin of atopic dermatitis patients with psoriasiform reaction during dupilumab treatment.
    Br J Dermatol. 2020 Aug 6. doi: 10.1111/bjd.19464.
    PubMed     Abstract available


    July 2020
  40. WILKINSON MJ, Gyorki DE
    Extent of ulceration in cutaneous melanoma: is this biomarker ready for primetime?
    Br J Dermatol. 2020 Jul 29. doi: 10.1111/bjd.19386.
    PubMed    


  41. RAFEI-SHAMSABADI D
    GNAQ/11 mutant nonuveal melanoma: same same but different.
    Br J Dermatol. 2020 Jul 28. doi: 10.1111/bjd.19335.
    PubMed    


  42. SHEEN YS, Chu CY
    Co-occurrence of TERT promotor mutations with BRAF or NRAS alterations correlates with worse prognosis in melanoma.
    Br J Dermatol. 2020 Jul 22. doi: 10.1111/bjd.19416.
    PubMed    


  43. BEHBAHANI S, Malerba S, Samie FH
    Racial and Ethnic Differences in the Clinical Presentation and Outcomes of Acral Lentiginous Melanoma.
    Br J Dermatol. 2020 Jul 19. doi: 10.1111/bjd.19406.
    PubMed     Abstract available


  44. GOETH H, Koller M, Hegemann MV, Drexler K, et al
    Active versus standard sun protection in patients with melanoma stage I or II: A randomised controlled feasibility trial assessing compliance with sun protection and quality of life.
    Br J Dermatol. 2020 Jul 11. doi: 10.1111/bjd.19395.
    PubMed     Abstract available


  45. BAI X, Flaherty KT
    Targeted and immunotherapies in BRAF mutant melanoma - where we are standing and what to expect.
    Br J Dermatol. 2020 Jul 11. doi: 10.1111/bjd.19394.
    PubMed     Abstract available


  46. ALFONSO JH, Martinsen JI, Weiderpass E, Pukkala E, et al
    Occupation and cutaneous melanoma: a 45-year historical cohort study of 14.9 million people in five Nordic countries.
    Br J Dermatol. 2020 Jul 6. doi: 10.1111/bjd.19379.
    PubMed     Abstract available


    June 2020
  47. HOLLESTEIN LM, Nijsten T
    Survival is excellent for most patients with thin melanoma, but patients may die from thin melanoma.
    Br J Dermatol. 2020 Jun 15. doi: 10.1111/bjd.19208.
    PubMed    


  48. OLSEN CM
    Global trends in melanoma mortality differ by sex and age.
    Br J Dermatol. 2020 Jun 8. doi: 10.1111/bjd.19166.
    PubMed    


  49. MANRIQUE-SILVA E, Rachakonda S, Millan-Esteban D, Garcia-Casado Z, et al
    Clinical, environmental, and histological distribution of BRAF, NRAS and TERT promoter mutations among cutaneous melanoma patients. A retrospective study of 563 patients.
    Br J Dermatol. 2020 Jun 7. doi: 10.1111/bjd.19297.
    PubMed     Abstract available


    May 2020
  50. JANDA M, Swetter SM, Horsham C, Soyer HP, et al
    Virtual melanoma checks during a pandemic.
    Br J Dermatol. 2020 May 29. doi: 10.1111/bjd.19255.
    PubMed     Abstract available


  51. BEHBAHANI S, Malerba S, Samie FH
    Acral Lentiginous Melanoma: Clinicopathologic Characteristics and Survival Outcomes in the United States National Cancer Database 2004 -2016.
    Br J Dermatol. 2020 May 14. doi: 10.1111/bjd.19211.
    PubMed     Abstract available


  52. TALAGANIS JA, Gregoriou S, Stratigos AJ
    Stress and melanoma. Myth or reality?
    Br J Dermatol. 2020 May 10. doi: 10.1111/bjd.19035.
    PubMed    


  53. KARAKOUSIS G
    Immune checkpoint blockade: an urgent call for biomarkers to help guide treatment.
    Br J Dermatol. 2020;182:1085-1086.
    PubMed    


    April 2020
  54. LOTZ M, Budden T, Furney SJ, Viros A, et al
    Molecular subtype, biological sex and age shape melanoma tumour evolution.
    Br J Dermatol. 2020 Apr 13. doi: 10.1111/bjd.19128.
    PubMed     Abstract available


  55. PORTELLI F, Galli F, Cattaneo L, Cossa M, et al
    The prognostic impact of the extent of ulceration in clinical stage I-II melanoma patients: A multicenter study of the Italian Melanoma Intergroup (IMI).
    Br J Dermatol. 2020 Apr 13. doi: 10.1111/bjd.19120.
    PubMed     Abstract available


  56. MUTHIAH S, Polubothu S, Husain A, Oliphant T, et al
    A mosaic variant in MAP2K1 is associated with giant naevus-spilus type congenital melanocytic naevus and melanoma development.
    Br J Dermatol. 2020 Apr 9. doi: 10.1111/bjd.19118.
    PubMed     Abstract available


  57. CUST AE
    Gene-environment interactions and melanoma risk.
    Br J Dermatol. 2020 Apr 1. doi: 10.1111/bjd.18986.
    PubMed    


  58. THOMPSON AR, Cockayne S
    It's the worry that got him in the end: the importance in treating melanoma holistically and dealing with fear of recurrence.
    Br J Dermatol. 2020;182:821-822.
    PubMed    


    March 2020
  59. FREDEAU L, Bohelay G, Shourick J, Piver D, et al
    Paraneoplastic neutrophilic leukemoid reaction in a melanoma patient: association between tumour volume and leukocytosis.
    Br J Dermatol. 2020 Mar 30. doi: 10.1111/bjd.19059.
    PubMed     Abstract available


  60. ROBINSON JK, Abou-El-Seoud D, Reavy R, Turrisi R, et al
    Persistence of partner-assisted skin self-examination supported by "being in this together": a randomized trial.
    Br J Dermatol. 2020 Mar 28. doi: 10.1111/bjd.19048.
    PubMed     Abstract available


  61. OLAMIJU B, Leventhal JS
    Near total body vitiligo secondary to immunotherapy for metastatic melanoma.
    Br J Dermatol. 2020 Mar 9. doi: 10.1111/bjd.18944.
    PubMed    


  62. VON SCHUCKMANN LA, Khosrotehrani K, Ghiasvand R, Hughes MCB, et al
    Statins may reduce disease recurrence in patients with ulcerated primary melanoma.
    Br J Dermatol. 2020 Mar 4. doi: 10.1111/bjd.19012.
    PubMed     Abstract available


  63. ISAKSSON K, Mikiver R, Eriksson H, Lapins J, et al
    Survival in 31 670 patients with thin melanomas - a Swedish population-based study.
    Br J Dermatol. 2020 Mar 4. doi: 10.1111/bjd.19015.
    PubMed     Abstract available


  64. YANG DD, Salciccioli JD, Marshall DC, Sheri A, et al
    Trends in malignant melanoma mortality in 31 countries from 1985 to 2015.
    Br J Dermatol. 2020 Mar 4. doi: 10.1111/bjd.19010.
    PubMed     Abstract available


  65. WONG AYS, Froslev T, Dearing L, Forbes HJ, et al
    The association between partner bereavement and melanoma: cohort studies in the U.K. and Denmark.
    Br J Dermatol. 2020 Mar 3. doi: 10.1111/bjd.18889.
    PubMed     Abstract available


    February 2020
  66. CHI CC
    Dermoscopy and reflectance confocal microscopy for early diagnosis of amelanotic/hypomelanotic melanoma: still a long way to go?
    Br J Dermatol. 2020 Feb 23. doi: 10.1111/bjd.18893.
    PubMed    


  67. LIVINGSTONE E, Zaremba A, Horn S, Ugurel S, et al
    GNAQ and GNA11 mutant non-uveal melanoma, a subtype distinct from both cutaneous and uveal melanoma.
    Br J Dermatol. 2020 Feb 16. doi: 10.1111/bjd.18947.
    PubMed     Abstract available


  68. FILONI A, Lospalluti L, Zanframundo G, De Marco A, et al
    Light brown structureless areas as predictor of melanoma in situ.
    Br J Dermatol. 2020 Feb 4. doi: 10.1111/bjd.18926.
    PubMed     Abstract available


  69. CUST AE
    Who dies from thin melanoma?
    Br J Dermatol. 2020 Feb 3. doi: 10.1111/bjd.18871.
    PubMed    


    January 2020
  70. BUJA A, Rivera M, De Polo A, Zorzi M, et al
    Real-world data for direct stage-specific costs of melanoma healthcare.
    Br J Dermatol. 2020 Jan 29. doi: 10.1111/bjd.18896.
    PubMed     Abstract available


  71. POLESIE S, Gillstedt M, Paoli J, Osmancevic A, et al
    Methotrexate treatment for psoriasis patients and risk of cutaneous melanoma: a nested case-control study.
    Br J Dermatol. 2020 Jan 25. doi: 10.1111/bjd.18887.
    PubMed     Abstract available


  72. WARD SV, Gibbs DC, Orlow I, Thomas NE, et al
    Association of IRF4 SNP rs12203592 with melanoma-specific survival.
    Br J Dermatol. 2020 Jan 20. doi: 10.1111/bjd.18881.
    PubMed     Abstract available


  73. DAI W, Liu H, Liu Y, Xu X, et al
    Genetic variants in the folate metabolic pathway genes predict melanoma-specific survival.
    Br J Dermatol. 2020 Jan 18. doi: 10.1111/bjd.18878.
    PubMed     Abstract available


  74. CRAIG S, Viros A
    New biomarkers improve stratification of patients with melanoma.
    Br J Dermatol. 2020;182:5-6.
    PubMed    


    December 2019
  75. THOMPSON JF, Friedman EB
    The intriguing association between smoking and reduced melanoma risk.
    Br J Dermatol. 2019 Dec 23. doi: 10.1111/bjd.18728.
    PubMed    


  76. HARTMAN RI, Xue Y, Singer S, Markossian TW, et al
    Modeling the Value of Risk Stratified Skin Cancer Screening of Asymptomatic Patients by Dermatologists.
    Br J Dermatol. 2019 Dec 22. doi: 10.1111/bjd.18816.
    PubMed     Abstract available


  77. DOCAMPO-SIMON A, Sanchez-Pujol MJ, Belinchon-Romero I, Niveiro M, et al
    Image Gallery: Haematogenous metastasis of melanoma mimicking lymphangioma.
    Br J Dermatol. 2019 Dec 17. doi: 10.1111/bjd.18723.
    PubMed    


  78. BETZ-STABLEIN B, Koh U, Plasmeijer E, Janda M, et al
    Self-reported naevus density may lead to misclassification of melanoma risk.
    Br J Dermatol. 2019 Dec 12. doi: 10.1111/bjd.18802.
    PubMed     Abstract available


  79. MCMENIMAN EK, Duffy DL, Jagirdar K, Lee KJ, et al
    The interplay of sun-damage and genetic risk in Australian multiple and single primary melanoma cases and controls.
    Br J Dermatol. 2019 Dec 3. doi: 10.1111/bjd.18777.
    PubMed     Abstract available


    November 2019
  80. BELL KJL
    Causal inference in melanoma epidemiology using Mendelian randomization.
    Br J Dermatol. 2019 Nov 28. doi: 10.1111/bjd.18646.
    PubMed    


  81. ROBINSON JK
    Frequency of 'regular' skin checks by dermatologists for melanoma survivors.
    Br J Dermatol. 2019 Nov 27. doi: 10.1111/bjd.18626.
    PubMed    


  82. WEBER J, Glutsch V, Geissinger E, Haug L, et al
    Neoadjuvant Immunotherapy with combined Ipilimumab and Nivolumab in Melanoma Patients with Primary or In-transit Disease.
    Br J Dermatol. 2019 Nov 26. doi: 10.1111/bjd.18739.
    PubMed     Abstract available


  83. OLSEN CM, Pandeya N, Law MH, MacGregor S, et al
    Does polygenic risk influence associations between sun exposure and melanoma?: a prospective cohort analysis.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18703.
    PubMed     Abstract available


  84. LAN J, Wen J, Cao S, Yin T, et al
    The diagnostic accuracy of dermoscopy and reflectance confocal microscopy for amelanotic/hypomelanotic melanoma: a systematic review and meta-analysis.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18722.
    PubMed     Abstract available


  85. FUJIMURA T, Tanita K, Sato Y, Lyu C, et al
    Immune checkpoint inhibitor-induced vitiligo in advanced melanoma could be related to increased levels of CCL19.
    Br J Dermatol. 2019 Nov 20. doi: 10.1111/bjd.18721.
    PubMed     Abstract available


  86. JOHANSSON P
    Differences between acral and nonacral melanoma genomes.
    Br J Dermatol. 2019 Nov 19. doi: 10.1111/bjd.18615.
    PubMed    


  87. DEL REGNO L, Louveau B, Battistella M, Sadoux A, et al
    Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort.
    Br J Dermatol. 2019 Nov 1. doi: 10.1111/bjd.18641.
    PubMed     Abstract available


  88. DUFFY DL, Lee KJ, Jagirdar K, Pflugfelder A, et al
    Naevus count and MC1R R alleles contribute to melanoma risk.
    Br J Dermatol. 2019;181:e119-e142.
    PubMed     Abstract available


    October 2019
  89. AGUILAR JA, Irurzun AL, Bayona JIY, Rodriguez MA, et al
    Image Gallery: Zosteriform metastasis from melanoma.
    Br J Dermatol. 2019 Oct 30. doi: 10.1111/bjd.18567.
    PubMed    


  90. HOWARD M, Xie C, Wee E, Wolfe R, et al
    Acral lentiginous melanoma: differences in survival compared to other subtypes.
    Br J Dermatol. 2019 Oct 19. doi: 10.1111/bjd.18620.
    PubMed     Abstract available


  91. GRAN S
    Vitiligo and skin cancer: is it a question of ethnicity?
    Br J Dermatol. 2019 Oct 16. doi: 10.1111/bjd.18533.
    PubMed    


  92. TOLAND AE
    Developing risk prediction models for melanoma: balancing better predictive value with ease of clinical implementation.
    Br J Dermatol. 2019 Oct 13. doi: 10.1111/bjd.18531.
    PubMed    


  93. DEINLEIN T, Longo C, Schulter G, Pizzichetta MA, et al
    The prevailing dermoscopic vascular pattern in melanoma is influenced by tumor thickness and pigmentation type.
    Br J Dermatol. 2019 Oct 12. doi: 10.1111/bjd.18610.
    PubMed     Abstract available


    September 2019
  94. CLAESON M, Baade P, Brown S, Soyer HP, et al
    Clinicopathological factors associated with death from thin (</=1.00mm) melanoma.
    Br J Dermatol. 2019 Sep 28. doi: 10.1111/bjd.18560.
    PubMed     Abstract available


  95. KOSTAKI M, Plaka M, Stergiopoulou A, Kypreou K, et al
    Trends in epidemiology of melanoma in situ in Greece: Data from a melanoma reference center during the period 2000-2018.
    Br J Dermatol. 2019 Sep 23. doi: 10.1111/bjd.18551.
    PubMed     Abstract available


  96. GIBSON JAG, Dobbs TD, Griffiths R, Song J, et al
    The Association of Smoking and Socioeconomic status on Cutaneous Melanoma: a population based, data linkage, case-control study.
    Br J Dermatol. 2019 Sep 17. doi: 10.1111/bjd.18526.
    PubMed     Abstract available


  97. CUST AE, Badcock C, Smith J, Thomas NE, et al
    A risk prediction model for development of subsequent primary melanoma in a population-based cohort.
    Br J Dermatol. 2019 Sep 14. doi: 10.1111/bjd.18524.
    PubMed     Abstract available


  98. BAILEY EE, Mayer JE, Geller AC, Johnson TM, et al
    Role of the partner/spouse in melanoma discovery and related health behaviors and practices.
    Br J Dermatol. 2019 Sep 5. doi: 10.1111/bjd.18478.
    PubMed     Abstract available


  99. STILLER HT, Mikiver R, Uppugunduri S, Lindholm C, et al
    Health Related Quality of Life in Melanoma Patients - characterization of a Swedish cohort.
    Br J Dermatol. 2019 Sep 5. doi: 10.1111/bjd.18486.
    PubMed     Abstract available


    August 2019
  100. GOLDINGER SM, Valeska Matter A, Urner-Bloch U, Narainsing J, et al
    Binimetinib in heavily pretreated NRAS-mutant Melanoma Patients with Brain Metastases.
    Br J Dermatol. 2019 Aug 22. doi: 10.1111/bjd.18449.
    PubMed     Abstract available


  101. SHEEN YS, Tan KT, Tse KP, Liao YH, et al
    Genetic Alterations in Primary Melanoma in Taiwan.
    Br J Dermatol. 2019 Aug 13. doi: 10.1111/bjd.18425.
    PubMed     Abstract available


  102. FEARFIELD L, Nobbs J, Petruckevitch A, Harland C, et al
    Severe vitamin D deficiency associated with BRAF mutated melanoma.
    Br J Dermatol. 2019 Aug 5. doi: 10.1111/bjd.18413.
    PubMed     Abstract available


  103. VUONG K, Armstrong BK, Drummond M, Hopper JL, et al
    Development and external validation study of a melanoma risk prediction model incorporating clinically-assessed naevi and solar lentigines.
    Br J Dermatol. 2019 Aug 4. doi: 10.1111/bjd.18411.
    PubMed     Abstract available


    July 2019
  104. GAMBICHLER T, Schroter U, Hoxtermann S, Susok L, et al
    Decline of PD-1 positive circulating T regulatory cells predicting more favorable clinical outcome of melanoma patients under immune checkpoint blockade.
    Br J Dermatol. 2019 Jul 30. doi: 10.1111/bjd.18379.
    PubMed     Abstract available


  105. RIBERO S
    Synergy between MC1R mutations and a high naevus count in increasing melanoma risk in the general population.
    Br J Dermatol. 2019 Jul 28. doi: 10.1111/bjd.18301.
    PubMed    


  106. GAMBICHLER T, Susok L, Fels M, Schneider-Gold C, et al
    Autoimmune radiculoplexus neuropathy under adjuvant nivolumab treatment of a female melanoma patient.
    Br J Dermatol. 2019 Jul 19. doi: 10.1111/bjd.18358.
    PubMed     Abstract available


  107. OLSEN CM
    Reproductive factors and risk of melanoma: still unresolved.
    Br J Dermatol. 2019 Jul 9. doi: 10.1111/bjd.18136.
    PubMed    


  108. ARMSTRONG J
    Bioenergetic cellular index: a clinical biomarker to identify metabolic adaption in melanoma?
    Br J Dermatol. 2019;181:15-16.
    PubMed    


  109. FRANKE V
    Talimogene laherparepvec monotherapy, an elegant alternative to systemic immunotherapy for the treatment of early metastatic melanoma.
    Br J Dermatol. 2019;181:20-21.
    PubMed    


  110. TOLAND AE
    POT1 pathogenic variants: not all telomere pathway genes are equal in risk of hereditary cutaneous melanoma.
    Br J Dermatol. 2019;181:14-15.
    PubMed    


    June 2019
  111. KIM HS, Kim HJ, Hong ES, Kim KB, et al
    The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea.
    Br J Dermatol. 2019 Jun 24. doi: 10.1111/bjd.18247.
    PubMed     Abstract available


  112. LIYANAGE UE, Law MH, Barrett JH, Iles MM, et al
    Is there a causal relationship between vitamin D and melanoma risk? : A Mendelian randomization study.
    Br J Dermatol. 2019 Jun 19. doi: 10.1111/bjd.18238.
    PubMed     Abstract available


  113. MCINERNEY-LEO AM, Finnane A
    The personal touch: does the communication method affect response to melanoma genetic risk?
    Br J Dermatol. 2019;180:1288-1289.
    PubMed    


    May 2019
  114. CALBET-LLOPART N, Potrony M, Tell-Marti G, Carrera C, et al
    Detection of cell-free circulating BRAF(V) (600E) by droplet digital PCR in melanoma and non-melanoma patients under dermatological surveillance.
    Br J Dermatol. 2019 May 18. doi: 10.1111/bjd.18147.
    PubMed     Abstract available


  115. RUSSELL-JONES R
    A Brighter Future for Melanoma.
    Br J Dermatol. 2019 May 11. doi: 10.1111/bjd.18122.
    PubMed     Abstract available


  116. KIM TH, Kim HJ, Seo JW, Song KH, et al
    Efficacy and clinical significance of omitting blue dye injection during sentinel lymph node biopsy before Mohs micrographic surgery for malignant melanoma of the lower extremities.
    Br J Dermatol. 2019 May 11. doi: 10.1111/bjd.18121.
    PubMed     Abstract available


  117. ELLIS R, Tang D, Nasr B, Greenwood A, et al
    Epidermal AMBRA1 and Loricrin; a paradigm shift in the prognostication and stratification of AJCC stage I melanomas.
    Br J Dermatol. 2019 May 6. doi: 10.1111/bjd.18086.
    PubMed     Abstract available


  118. VENTURA A, Pitocco R, Di Stefani A, Cota C, et al
    Image Gallery: Peculiar subungual localization of a second primary melanoma during BRAF inhibitors treatment for metastatic melanoma: case report.
    Br J Dermatol. 2019;180:e142.
    PubMed    


    April 2019
  119. ELEN-LIRA F, Podlipnik S, Potrony M, Tell-Marti G, et al
    Inherited MC1R variants in melanoma patients are associated with better survival in females.
    Br J Dermatol. 2019 Apr 23. doi: 10.1111/bjd.18024.
    PubMed     Abstract available


  120. GASPARINI G, Madjlessi N, Delyon J, Carmisciano L, et al
    Usefulness of the "two-step method" of digital follow-up in early stage melanoma detection in at high risk French patients - A retrospective 4-year study.
    Br J Dermatol. 2019 Apr 12. doi: 10.1111/bjd.18006.
    PubMed     Abstract available


  121. DIENG M, Morton RL, Costa DSJ, Butow PN, et al
    Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12-month follow-up results of a randomised controlled trial.
    Br J Dermatol. 2019 Apr 9. doi: 10.1111/bjd.17990.
    PubMed     Abstract available


  122. SCARFI F, Gori A, Topa A, Trane L, et al
    Image Gallery: In vivo fluorescence-advanced videodermatoscopy for the characterization of skin melanocytic pigmented lesions.
    Br J Dermatol. 2019;180:e104.
    PubMed    


    March 2019
  123. ELIAS ML, Lambert WC
    Surgical Management of Localized Melanoma: A National Cancer Database Retrospective Review.
    Br J Dermatol. 2019 Mar 25. doi: 10.1111/bjd.17901.
    PubMed     Abstract available


  124. ROBERTS MR, Asgari MM, Toland AE
    Genome-wide association studies and polygenic risk scores for skin cancer: clinically useful yet?
    Br J Dermatol. 2019 Mar 25. doi: 10.1111/bjd.17917.
    PubMed     Abstract available


  125. DUFFY DL, Lee KJ, Jagirdar K, Pflugfelder A, et al
    High naevus count and MC1R red hair alleles contribute synergistically to increased melanoma risk.
    Br J Dermatol. 2019 Mar 1. doi: 10.1111/bjd.17833.
    PubMed     Abstract available


    February 2019
  126. RESSLER J, Silmbrod R, Stepan A, Tuchmann F, et al
    T-VEC in advanced Melanoma - Complete response in a heart and kidney transplant patient: A case report.
    Br J Dermatol. 2019 Feb 18. doi: 10.1111/bjd.17783.
    PubMed     Abstract available


  127. STOER NC, Botteri E, Ghiasvand R, Busund M, et al
    Reproductive factors and risk of melanoma: a population-based cohort study.
    Br J Dermatol. 2019 Feb 12. doi: 10.1111/bjd.17771.
    PubMed     Abstract available


  128. HALK AB, Potjer TP, Kukutsch NA, Vasen HFA, et al
    Surveillance for familial melanoma: recommendations from a national centre of expertise.
    Br J Dermatol. 2019 Feb 11. doi: 10.1111/bjd.17767.
    PubMed     Abstract available


  129. ZOUTENDIJK J, Tio D, Koljenovic S, van den Bos RR, et al
    Nine percent of biopsy proven lentigo maligna are reclassified as lentigo maligna melanoma after surgery.
    Br J Dermatol. 2019 Feb 4. doi: 10.1111/bjd.17714.
    PubMed     Abstract available


  130. CHAN MP
    Refining the ever-evolving molecular landscape of spitzoid melanocytic neoplasms.
    Br J Dermatol. 2019;180:262.
    PubMed    


    January 2019
  131. JIYAD Z, Akhras V
    Incidence of melanoma and outcomes of longitudinal melanonychia in a cohort of cases referred to a London dermatology department.
    Br J Dermatol. 2019 Jan 4. doi: 10.1111/bjd.17607.
    PubMed     Abstract available


  132. SCHILLING B, Wiesner T
    Tackling melanoma by adjuvant therapy: why, whom and how?
    Br J Dermatol. 2019;180:1-2.
    PubMed    


  133. VAN AKKOOI ACJ, Hayes A
    Recent developments in lymph node surgery for melanoma.
    Br J Dermatol. 2019;180:5-7.
    PubMed    


  134. UZUNCAKMAK TK, Akay BN, Ozkanli S
    Different dermoscopic features of clonal seborrhoeic keratoses.
    Br J Dermatol. 2019;180:197-198.
    PubMed    


    December 2018
  135. MIURA K, Olsen CM, Rea S, Marsden J, et al
    Do airline pilots and cabin crew have raised risks of melanoma and other skin cancers? Systematic review and meta-analysis.
    Br J Dermatol. 2018 Dec 26. doi: 10.1111/bjd.17586.
    PubMed     Abstract available


  136. FENTON GL, Smit AK, Keogh L, Cust AE, et al
    Exploring the Emotional and Behavioural Reactions to Receiving Personalised Melanoma Genomic Risk Information: A Qualitative Study.
    Br J Dermatol. 2018 Dec 22. doi: 10.1111/bjd.17582.
    PubMed     Abstract available


  137. NAJERA L, Alonso-Juarranz M, Garrido M, Ballestin C, et al
    Prognostic implications of markers of the metabolic phenotype in human cutaneous melanoma.
    Br J Dermatol. 2018 Dec 7. doi: 10.1111/bjd.17513.
    PubMed     Abstract available


  138. FOX JA, Langbecker D, Rosenberg J, Ekberg S, et al
    Uncertain diagnosis and prognosis in advanced melanoma: A qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies.
    Br J Dermatol. 2018 Dec 4. doi: 10.1111/bjd.17511.
    PubMed     Abstract available


    November 2018
  139. CORRIE PG, Terheyden P, Ten Tije AJ, Herbst R, et al
    A prospective, observational safety study of patients with BRAF(V) (600) -mutated unresectable or metastatic melanoma treated with vemurafenib [Zelboraf Safety Study (ZeSS)].
    Br J Dermatol. 2018 Nov 29. doi: 10.1111/bjd.17465.
    PubMed     Abstract available


  140. POTRONY M, Puig-Butille JA, Ribera-Sola M, Iyer V, et al
    POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
    Br J Dermatol. 2018 Nov 19. doi: 10.1111/bjd.17443.
    PubMed     Abstract available


  141. MAEDA T, Yoshino K, Nagai K, Oaku S, et al
    Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients.
    Br J Dermatol. 2018 Nov 17. doi: 10.1111/bjd.17434.
    PubMed     Abstract available


  142. OKIYAMA N, Inoue S, Saito A, Nakamura Y, et al
    Antihelix/helix violaceous macules in Japanese patients with anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis.
    Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17431.
    PubMed     Abstract available


  143. VERAITCH O, Lewis F, Craythorne E, Calonje E, et al
    Management of vulval melanoma in situ with imiquimod.
    Br J Dermatol. 2018 Nov 15. doi: 10.1111/bjd.17433.
    PubMed     Abstract available


    October 2018
  144. VERYKIOU S, Alexander M, Edwards N, Plummer R, et al
    Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma.
    Br J Dermatol. 2018 Oct 19. doi: 10.1111/bjd.17333.
    PubMed     Abstract available


    September 2018
  145. KOREKAWA A, Akasaka E, Rokunohe D, Fukui T, et al
    Nagashima-type palmoplantar keratoderma and malignant melanoma in Japanese patients.
    Br J Dermatol. 2018 Sep 26. doi: 10.1111/bjd.17251.
    PubMed     Abstract available


  146. ROGIERS A, Thomas D, Vander Borght S, van den Oord JJ, et al
    Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
    Br J Dermatol. 2018 Sep 24. doi: 10.1111/bjd.17250.
    PubMed     Abstract available


  147. XU S, Stump TK, Jain J, Alshurafa N, et al
    Variation in daily ultraviolet light exposure and sun protection behaviours of melanoma survivors: an observational single-arm pilot study with a wearable sensor.
    Br J Dermatol. 2018 Sep 12. doi: 10.1111/bjd.17196.
    PubMed     Abstract available


  148. BRANCACCIO G, Napolitano S, Troiani T, Franco R, et al
    Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC?
    Br J Dermatol. 2018 Sep 5. doi: 10.1111/bjd.17145.
    PubMed     Abstract available


  149. MATTHEWS NH, Risica PM, Ferris LK, Beatson M, et al
    Psychosocial impact of skin biopsies in the setting of melanoma screening - A cross-sectional survey.
    Br J Dermatol. 2018 Sep 5. doi: 10.1111/bjd.17134.
    PubMed     Abstract available


    August 2018
  150. FOGARTY GB, McLaren KR, Moutrie Z, Poon TSC, et al
    Locally advanced skin cancers of the frail and elderly - consider adaptive split course radiotherapy (ASCRT).
    Br J Dermatol. 2018 Aug 16. doi: 10.1111/bjd.17037.
    PubMed     Abstract available


  151. CUST AE, Aitken J, Baade P, Whiteman D, et al
    Why a randomised melanoma screening trial may be a good idea.
    Br J Dermatol. 2018 Aug 13. doi: 10.1111/bjd.17089.
    PubMed     Abstract available


  152. VAN DOORN R
    Methylation marks melanoma metastasis.
    Br J Dermatol. 2018;179:250-251.
    PubMed    


    June 2018
  153. KEOHANE SG, Proby CM, Newlands C, Motley RJ, et al
    The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, United Kingdom.
    Br J Dermatol. 2018 Jun 19. doi: 10.1111/bjd.16892.
    PubMed     Abstract available


  154. FARAH M, Nagarajan P, Curry JL, Tang Z, et al
    Spitzoid melanoma with histopathologic features of ALK gene rearrangement exhibiting ALK copy number gain: A novel mechanism of ALK activation in spitzoid neoplasia.
    Br J Dermatol. 2018 Jun 13. doi: 10.1111/bjd.16881.
    PubMed     Abstract available


  155. HALVORSEN JA, Loberg M, Gjersvik P, Roscher I, et al
    Why a randomized melanoma screening trial is not a good idea.
    Br J Dermatol. 2018 Jun 12. doi: 10.1111/bjd.16784.
    PubMed    


  156. PODLIPNIK S, Moreno-Ramirez D, Carrera C, Barreiro A, et al
    Cost-effectiveness analysis of imaging strategy for an intensive follow-up of patients with AJCC stage IIB, IIC and III malignant melanoma.
    Br J Dermatol. 2018 Jun 7. doi: 10.1111/bjd.16833.
    PubMed     Abstract available


  157. STENEHJEM JS, Veierod MB, Nilsen LT, Ghiasvand R, et al
    Anthropometric factors and Breslow thickness: Prospective data on 2570 cutaneous melanoma cases in the population-based Janus Cohort.
    Br J Dermatol. 2018 Jun 1. doi: 10.1111/bjd.16825.
    PubMed     Abstract available


    May 2018
  158. WAN MT, Ming ME
    Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal.
    Br J Dermatol. 2018 May 15. doi: 10.1111/bjd.16785.
    PubMed     Abstract available


  159. CAYUELA A, Cayuela L, Rodriguez-Dominguez S, Lorente AI, et al
    Is melanoma mortality declining in Spain? Analysis of trends 1975-2016.
    Br J Dermatol. 2018 May 14. doi: 10.1111/bjd.16777.
    PubMed     Abstract available


  160. FUJISAWA Y
    Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors.
    Br J Dermatol. 2018 May 7. doi: 10.1111/bjd.16689.
    PubMed    


  161. KRAEMER KH, Tamura D, Khan SG
    Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers.
    Br J Dermatol. 2018;178:1009.
    PubMed    


    April 2018
  162. RAUWERDINK DJW, Roach REJ, Etty M, Kukutsch NA, et al
    Melanoma diagnosis during periodic surveillance of patients with multiple atypical naevi.
    Br J Dermatol. 2018 Apr 28. doi: 10.1111/bjd.16708.
    PubMed     Abstract available


  163. BAN L, Labbouz S, Grindlay D, Batchelor J, et al
    Risk of skin cancer in people with vitiligo: a systematic review and meta-analysis.
    Br J Dermatol. 2018 Apr 28. doi: 10.1111/bjd.16703.
    PubMed     Abstract available


  164. LANGAN EA, Gratz V, Billmann F, Zillikens D, et al
    Does the gastrointestinal microbiome contribute to the "obesity paradox" in melanoma survival?
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16681.
    PubMed     Abstract available


  165. KIM J, Kim YH, Park B, Seo HM, et al
    Multispectral ex vivo photoacoustic imaging of cutaneous melanoma for better selection of the excision margin.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16677.
    PubMed     Abstract available


  166. MACHET L, Zaragoza J, Finon A, Garnier M, et al
    Baseline neutrophil to lymphocyte ratio in patients with advanced melanoma treated with immune check point inhibitors.
    Br J Dermatol. 2018 Apr 16. doi: 10.1111/bjd.16675.
    PubMed     Abstract available


  167. HAAS L, Wiesner T, Obenauf AC
    A new era of proactive melanoma therapy: hit hard, hit early.
    Br J Dermatol. 2018;178:817-820.
    PubMed    


    March 2018
  168. VU M, Adler NR, Wee E, Wolfe R, et al
    Impact of naevus association on survival for nodular and superficial spreading melanomas.
    Br J Dermatol. 2018 Mar 24. doi: 10.1111/bjd.16556.
    PubMed     Abstract available


  169. FORSCHNER A, Keim U, Hofmann M, Spankuch I, et al
    Diagnostic accuracy of dermatofluoroscopy in cutaneous melanoma detection: Results of a prospective multicentre clinical study in 476 pigmented lesions.
    Br J Dermatol. 2018 Mar 22. doi: 10.1111/bjd.16565.
    PubMed     Abstract available


  170. MARCHAND A, Tallet A, Collin C, Cormier B, et al
    A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Br J Dermatol. 2018 Mar 1. doi: 10.1111/bjd.16499.
    PubMed     Abstract available


  171. BARRAGAN-ESTUDILLO ZF, Jesus-Silva MA, Chavez-Bourgeois MM, Brito J, et al
    Image Gallery: Transition pattern in acral melanoma.
    Br J Dermatol. 2018;178:e225.
    PubMed    


    February 2018
  172. LONGO C, Lallas A, Kyrgidis A, Bassoli S, et al
    Wide skin markings pattern - melanoma descriptor or patient-related factor?: reply from authors.
    Br J Dermatol. 2018 Feb 7. doi: 10.1111/bjd.16430.
    PubMed     Abstract available


  173. RISHPON A, Marchetti M, Marghoob A
    Wide skin markings pattern - melanoma descriptor or patient-related factor?
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16420.
    PubMed     Abstract available


  174. FUJISAWA Y, Yoshino K, Otsuka A, Funakoshi T, et al
    Baseline neutrophil to lymphocyte ratio combined with serum LDH level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population.
    Br J Dermatol. 2018 Feb 6. doi: 10.1111/bjd.16427.
    PubMed     Abstract available


  175. DANDO EE, Lim GFS, Ho J, James A, et al
    Image Gallery: Pigmented mammary Paget disease: a rare clinicopathological variant mimicking melanoma.
    Br J Dermatol. 2018;178:e143.
    PubMed    


  176. CUST AE
    Prognostic features for acral lentiginous melanoma.
    Br J Dermatol. 2018;178:311-312.
    PubMed    


  177. BELL KJL, Cust AE
    Beyond country-specific incidence and mortality: the global burden of melanoma.
    Br J Dermatol. 2018;178:315-316.
    PubMed    


    January 2018
  178. BORSARI S, Pampena R, Benati E, Bombonato C, et al
    In vivo dermoscopic and confocal microscopy multi-step algorithm to detect in situ melanomas.
    Br J Dermatol. 2018 Jan 21. doi: 10.1111/bjd.16364.
    PubMed     Abstract available


  179. LAINO AM, Berry EG, Jagirdar K, Lee KJ, et al
    Iris pigmented lesions as a marker of cutaneous melanoma risk: an Australian case-control study.
    Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16323.
    PubMed     Abstract available


  180. VERYKIOU S, Edwards N, Hill D
    How breakthroughs in translational research have impacted treatment strategies for melanoma.
    Br J Dermatol. 2018;178:5-8.
    PubMed    


  181. MUTHIAH S, Tang D, Nasr B, Verykiou S, et al
    A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma.
    Br J Dermatol. 2018;178:1-4.
    PubMed    


  182. WIESNER T, Zbyszewski A
    Progress in the diagnosis and therapy of melanoma.
    Br J Dermatol. 2018;178:12-14.
    PubMed    


  183. WEHNER MR
    Sunscreen and melanoma prevention: evidence and expectations.
    Br J Dermatol. 2018;178:15-16.
    PubMed    


  184. HWANG SJE, Fernandez-Penas P
    Pigmentary evolution with pembrolizumab use.
    Br J Dermatol. 2018;178:32-33.
    PubMed    


    December 2017
  185. MCINERNEY-LEO AM, Wheeler L, Sturm RA, Tan JM, et al
    Point mutation in p14(ARF) -specific exon 1beta of CDKN2A causing familial melanoma and astrocytoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16275.
    PubMed     Abstract available


  186. DE UNAMUNO BUSTOS B, Murria Estal R, Perez Simo G, Simarro Farinos J, et al
    Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
    Br J Dermatol. 2017 Dec 26. doi: 10.1111/bjd.16254.
    PubMed     Abstract available


  187. SALOMON G, Maza A, Boulinguez S, Paul C, et al
    Efficacy of anti-PD-1 on skin carcinomas and melanoma metastases in an Xeroderma Pigmentosum patient.
    Br J Dermatol. 2017 Dec 23. doi: 10.1111/bjd.16270.
    PubMed     Abstract available


  188. OLSEN CM, Wilson LF, Green AC, Biswas N, et al
    How many melanomas might be prevented if more people applied sunscreen regularly?
    Br J Dermatol. 2017 Dec 14. doi: 10.1111/bjd.16079.
    PubMed     Abstract available


    November 2017
  189. WINSLOW UC, Nordestgaard BG, Afzal S
    High plasma 25-hydroxyvitamin D and high risk of non-melanoma skin cancer: a Mendelian randomisation study of 97849 individuals.
    Br J Dermatol. 2017 Nov 16. doi: 10.1111/bjd.16127.
    PubMed     Abstract available


  190. DEL PUERTO C, Navarrete-Dechent C, Molgo M, Camargo CA Jr, et al
    Immunohistochemical expression of vitamin D receptor in melanocytic nevi and cutaneous melanoma. A case-control study.
    Br J Dermatol. 2017 Nov 6. doi: 10.1111/bjd.16103.
    PubMed     Abstract available


    October 2017
  191. TRAN AD, Fogarty G, Nowak AK, Espinoza D, et al
    A systematic review and meta-analysis of utility estimates in melanoma.
    Br J Dermatol. 2017 Oct 27. doi: 10.1111/bjd.16098.
    PubMed     Abstract available


  192. SEO JW, Ha SM, Song KH
    Insulin-Like Growth Factor-II mRNA-Binding Protein 3 as a Novel Prognostic Biomarker for Acral Lentiginous Melanoma.
    Br J Dermatol. 2017 Oct 19. doi: 10.1111/bjd.16077.
    PubMed     Abstract available


  193. BASSOLI S, Kyrgidis A, Ciardo S, Casari A, et al
    Uncovering the diagnostic dermoscopic features of flat melanomas located on the lower limbs.
    Br J Dermatol. 2017 Oct 7. doi: 10.1111/bjd.16030.
    PubMed     Abstract available


  194. SCHAIDER H, Sturm RA
    The evolving universe of BRAF mutations in melanoma.
    Br J Dermatol. 2017;177:893.
    PubMed    


  195. ROBINSON JK, Spring B
    Personalized melanoma genomic risk information:perception of shared risk initiates sharing with family.
    Br J Dermatol. 2017;177:890-891.
    PubMed    


    September 2017
  196. SATTLER EC, Ertl-Wagner B, Pellegrini C, Peris K, et al
    Cutaneous melanoma in Birt-Hogg-Dube syndrome - part of the clinical spectrum?
    Br J Dermatol. 2017 Sep 4. doi: 10.1111/bjd.15937.
    PubMed     Abstract available


  197. ZNAOR A
    Melanoma burden, healthcare utilization and the potential for overdiagnosis in the elderly U.S. population.
    Br J Dermatol. 2017;177:625.
    PubMed    


    August 2017
  198. YOULDEN DR, Baade PD, Aitken JF, Green AC, et al
    Prognostic importance of a second invasive primary melanoma according to tumor stage.
    Br J Dermatol. 2017 Aug 3. doi: 10.1111/bjd.15863.
    PubMed     Abstract available


  199. BERK-KRAUSS J, Stein JA
    The role of access to care in acral lentiginous melanoma survival.
    Br J Dermatol. 2017;177:341-342.
    PubMed    


  200. HILL D, Lovat P
    Cover Image: Invasion of a cutaneous melanoma tumour.
    Br J Dermatol. 2017;177:599.
    PubMed    


    July 2017
  201. ADLER NR, Kelly JW, Haydon A, McLean CA, et al
    Clinicopathological characteristics and prognosis of patients with multiple primary melanomas.
    Br J Dermatol. 2017 Jul 28. doi: 10.1111/bjd.15855.
    PubMed     Abstract available


  202. DIAS-SANTAGATA D, Selim MA, Su Y, Peng Y, et al
    KIT Mutations and CD117 Overexpression Are Markers of Better Progression-Free Survival in Vulvar Melanomas.
    Br J Dermatol. 2017 Jul 22. doi: 10.1111/bjd.15836.
    PubMed     Abstract available


  203. TERAMOTO Y, Keim U, Gesierich A, Schuler G, et al
    Acral lentiginous melanoma - a skin cancer with unfavourable prognostic features. A study of the German Central Malignant Melanoma Registry (CMMR) in 2050 patients.
    Br J Dermatol. 2017 Jul 14. doi: 10.1111/bjd.15803.
    PubMed     Abstract available


  204. GIBBS DC, Ward SV, Orlow I, Cadby G, et al
    Functional melanoma-risk variant IRF4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas.
    Br J Dermatol. 2017 Jul 1. doi: 10.1111/bjd.15784.
    PubMed     Abstract available


  205. MAHER NG, Guitera P
    Imiquimod treatment for lentigo maligna: LIMIT-1 trial.
    Br J Dermatol. 2017;177:324-325.
    PubMed    


    June 2017
  206. SMIT AK, Keogh LA, Newson AJ, Butow PN, et al
    Does personalised melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?
    Br J Dermatol. 2017 Jun 19. doi: 10.1111/bjd.15744.
    PubMed     Abstract available


  207. KIM SK, Barker CA
    Outcomes of radiation therapy for advanced T3/T4 non-melanoma cutaneous squamous cell and basal cell carcinoma.
    Br J Dermatol. 2017 Jun 15. doi: 10.1111/bjd.15728.
    PubMed     Abstract available


  208. CERIO R, Moir G
    Palliative electrochemotherapy treatment of metastatic malignant melanoma.
    Br J Dermatol. 2017;176:1427.
    PubMed    


  209. JONES G
    Methotrexate increases the risk of melanoma: or does it?
    Br J Dermatol. 2017;176:1429-1430.
    PubMed    


    May 2017
  210. RIBERO S, Carrera C, Tell-Marti G, Pastorino C, et al
    Amelanotic melanoma in oculocutaneous albinism: a genetic, dermoscopic and reflectance confocal microscopy study.
    Br J Dermatol. 2017 May 27. doi: 10.1111/bjd.15687.
    PubMed     Abstract available


  211. SWETTER SM
    Challenges of treating melanoma in situ, lentigo maligna type: is pathological clearance the gold standard?
    Br J Dermatol. 2017;176:1115-1116.
    PubMed    


  212. ELLIS RA
    T-type calcium channels as potential biomarkers in melanoma.
    Br J Dermatol. 2017;176:1122.
    PubMed    


  213. KRENGEL S, Reyes-Mugica M
    Melanoma risk in congenital melanocytic naevi.
    Br J Dermatol. 2017;176:1114.
    PubMed    


    April 2017
  214. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease: reply from authors.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15626.
    PubMed     Abstract available


  215. SALEH DB
    RE: Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2017 Apr 29. doi: 10.1111/bjd.15619.
    PubMed     Abstract available


  216. ASGARI MM, Shen L, Sokil MM, Yeh I, et al
    Prognostics factors and survival in acral lentiginous melanoma.
    Br J Dermatol. 2017 Apr 22. doi: 10.1111/bjd.15600.
    PubMed     Abstract available


  217. ROCHA L, Menzies SW, Lo S, Avramidis M, et al
    Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy imaging of melanocytic lesions.
    Br J Dermatol. 2017 Apr 19. doi: 10.1111/bjd.15595.
    PubMed     Abstract available


  218. GUALANO MR, Osella-Abate S, Scaioli G, Marra E, et al
    Prognostic role of Histologic regression in primary cutaneous melanoma: A Systematic Review and Meta-analysis.
    Br J Dermatol. 2017 Apr 7. doi: 10.1111/bjd.15552.
    PubMed     Abstract available


  219. NIJSTEN T, Wakkee M
    The four Ws of skin cancer surveillance in patients with melanoma: Why? Who? When? Where?
    Br J Dermatol. 2017;176:839-841.
    PubMed    


  220. MONTAUDIE H, Pradelli J, Passeron T, Lacour JP, et al
    Pulmonary sarcoid-like granulomatosis induced by nivolumab.
    Br J Dermatol. 2017;176:1060-1063.
    PubMed     Abstract available


    March 2017
  221. LOTT JP, Wang Q, Titus LJ, Onega T, et al
    Temporal Trends in Healthcare Utilization following Primary Melanoma Diagnosis among Medicare Beneficiaries.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15530.
    PubMed     Abstract available


  222. KARIMKHANI C, Green AC, Nijsten T, Weinstock MA, et al
    The Global Burden of Melanoma: Results from Global Burden of Disease Study 2015.
    Br J Dermatol. 2017 Mar 30. doi: 10.1111/bjd.15510.
    PubMed     Abstract available


  223. KOGUCHI-YOSHIOKA H, Okiyama N, Iwamoto K, Matsumura Y, et al
    Intravenous immunoglobulin contributes to control anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis with palmar violaceous macules/papules.
    Br J Dermatol. 2017 Mar 27. doi: 10.1111/bjd.15499.
    PubMed     Abstract available


  224. LICCIARDELLO M, T Giura M, Rozzo G, Marra E, et al
    Arrhythmias in metastatic melanoma patient treated with targeted therapy and ICD implant.
    Br J Dermatol. 2017 Mar 10. doi: 10.1111/bjd.15447.
    PubMed     Abstract available


  225. RICHTIG G, Hoeller C, Kashofer K, Aigelsreiter A, et al
    Beyond the BRAFV600E hotspot - Biology and clinical implications of rare BRAF gene mutations in melanoma patients.
    Br J Dermatol. 2017 Mar 9. doi: 10.1111/bjd.15436.
    PubMed     Abstract available


    February 2017
  226. CORR M, Roulston G, King N, Dornan T, et al
    Living with 'melanoma'...for a day: a phenomenological analysis of medical students' simulated experiences.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15402.
    PubMed     Abstract available


  227. TSAI S, Scott JF, Keller JJ, Gerstenblith MR, et al
    Cutaneous malignancies identified on an inpatient Dermatology consult service.
    Br J Dermatol. 2017 Feb 23. doi: 10.1111/bjd.15401.
    PubMed     Abstract available


  228. JORDAN M, Ghoreschi K
    Anti-melanoma differentiation-associated protein 5 autoantibodies as a marker for dermatomyositis-associated interstitial lung disease.
    Br J Dermatol. 2017;176:294-295.
    PubMed    


    January 2017
  229. WOLNER ZJ, Marghoob AA, Pulitzer MP, Postow MA, et al
    A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma.
    Br J Dermatol. 2017 Jan 28. doi: 10.1111/bjd.15354.
    PubMed     Abstract available


  230. VANHAECKE C, Deilhes F, Chanal J, Regnier-Rosencher E, et al
    BRAFV600 inhibitor discontinuation after complete response in advanced melanoma. A retrospective analysis of 16 patients.
    Br J Dermatol. 2017 Jan 27. doi: 10.1111/bjd.15345.
    PubMed     Abstract available


  231. KUNTE C, Letule V, Gehl J, Dahlstroem K, et al
    Electrochemotherapy in the treatment of metastatic malignant melanoma: A prospective cohort study by InspECT.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15340.
    PubMed     Abstract available


  232. MINAGAWA A, Omodaka T, Koga H, Yokokawa Y, et al
    Nail apparatus melanoma thickness is associated with side and age.
    Br J Dermatol. 2017 Jan 24. doi: 10.1111/bjd.15318.
    PubMed     Abstract available


  233. KINSLER VA, O'Hare P, Bulstrode N, Calonje JE, et al
    Melanoma in congenital melanocytic naevi.
    Br J Dermatol. 2017 Jan 12. doi: 10.1111/bjd.15301.
    PubMed     Abstract available


    December 2016
  234. NEITTAANMAKI N, Salmivuori M, Polonen I, Jeskanen L, et al
    Hyperspectral imaging in detecting dermal invasion in lentigo maligna melanoma.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15267.
    PubMed     Abstract available


  235. USHER-SMITH JA, Kassianos AP, Emery JD, Abel GA, et al
    Identifying people at higher risk of melanoma across the U.K.: a primary-care-based electronic survey.
    Br J Dermatol. 2016 Dec 23. doi: 10.1111/bjd.15181.
    PubMed     Abstract available


  236. HERMS F, Franck N, Kramkimel N, Fichel F, et al
    Neutrophilic eccrine hidradenitis in 2 patients treated with BRAF inhibitors: a new cutaneous adverse event.
    Br J Dermatol. 2016 Dec 22. doi: 10.1111/bjd.15259.
    PubMed     Abstract available


  237. RICHTIG G, Richtig E, Kashofer K, Koch L, et al
    Testing and clinical implications for non-V600 BRAF mutations in metastatic NRASmt melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15222.
    PubMed     Abstract available


  238. LINOS E, Li WQ, Han J, Li T, et al
    Lifetime UV exposure and Lentigo Maligna Melanoma.
    Br J Dermatol. 2016 Dec 7. doi: 10.1111/bjd.15218.
    PubMed     Abstract available


  239. SPENDER LC, Inman GJ
    Fatal attractions? Correlations of CXCL12-CXCR4-CXCR7 expression with disease progression in melanoma and Kaposi sarcoma.
    Br J Dermatol. 2016;175:1140-1141.
    PubMed    


  240. YELAMOS O, Nehal KS
    Integrating clinical information, dermoscopy and reflectance confocal microscopy to improve the diagnostic accuracy and confidence of amelanotic and lightly pigmented melanomas.
    Br J Dermatol. 2016;175:1147-1148.
    PubMed    


  241. HAASS NK
    JNK-ERK signalling in melanoma: rewired or entangled?
    Br J Dermatol. 2016;175:1139-1140.
    PubMed    


  242. DIXON A, Steinman H, Anderson S, Nirenberg A, et al
    Routine usage of sentinel node biopsy in melanoma management must cease.
    Br J Dermatol. 2016;175:1340-1341.
    PubMed    


    November 2016
  243. SPEIGL L, Janssen N, Weide B, Pawelec G, et al
    Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma.
    Br J Dermatol. 2016 Nov 21. doi: 10.1111/bjd.15194.
    PubMed     Abstract available


  244. MAHER NG, Blumetti TP, Gomes EE, Cheng HM, et al
    Melanoma diagnosis may be a pitfall for optical coherence tomography assessment of equivocal amelanotic or hypomelanotic skin lesions.
    Br J Dermatol. 2016 Nov 18. doi: 10.1111/bjd.15187.
    PubMed     Abstract available


  245. POLESIE S, Gillstedt M, Sonnergren HH, Osmancevic A, et al
    Methotrexate Treatment and Risk for Cutaneous Malignant Melanoma - a Retrospective Comparative Registry-based Cohort Study.
    Br J Dermatol. 2016 Nov 10. doi: 10.1111/bjd.15170.
    PubMed     Abstract available


  246. BARRETT JH
    Telomere length and melanoma - is there a straightforward relationship?
    Br J Dermatol. 2016;175:865-866.
    PubMed    


  247. ELLIKER KR, Williams HC
    Detection of skin cancer odours using dogs: a step forward in melanoma detection training and research methodologies.
    Br J Dermatol. 2016;175:851-852.
    PubMed    


  248. EISEMANN N
    Routine health data in skin cancer screening evaluation.
    Br J Dermatol. 2016;175:862.
    PubMed    


    October 2016
  249. RICHTIG G, Byrom L, Kupsa R, Schaider H, et al
    Pregnancy as driver for melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15124.
    PubMed     Abstract available


  250. MAIQUES O, Macia A, Moreno S, Barcelo C, et al
    Immunohistochemical analysis of T-type calcium channels in acquired melanocytic nevi and melanoma.
    Br J Dermatol. 2016 Oct 8. doi: 10.1111/bjd.15121.
    PubMed     Abstract available


  251. O'SHEA SJ, Davies JR, Newton-Bishop JA
    Vitamin D, vitamin A, the primary melanoma transcriptome and survival.
    Br J Dermatol. 2016;175 Suppl 2:30-34.
    PubMed     Abstract available


    September 2016
  252. PIZZICHETTA MA, Kittler H, Stanganelli I, Ghigliotti G, et al
    Dermoscopic diagnosis of amelanotic/hypomelanotic melanoma.
    Br J Dermatol. 2016 Sep 28. doi: 10.1111/bjd.15093.
    PubMed     Abstract available


  253. WEINSTOCK MA, Lott JP, Wang Q, Titus LJ, et al
    Skin Biopsy Utilization and Melanoma Incidence among Medicare Beneficiaries.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15077.
    PubMed     Abstract available


  254. LO MC, Maraka J, Garioch J, John WG, et al
    Monitoring vitamin D in the melanoma patient - impact of sun avoidance on vitamin D levels of melanoma patients at a tertiary UK referral melanoma service.
    Br J Dermatol. 2016 Sep 17. doi: 10.1111/bjd.15062.
    PubMed     Abstract available


  255. FOX J
    A changing treatment paradigm: the role of palliative care in metastatic melanoma.
    Br J Dermatol. 2016;175:462-3.
    PubMed    


    June 2016
  256. WANG CC, Tang CH, Wang CY, Huang SY, et al
    Risk of skin cancer in chronic haemodialysis patients: a nationwide, population-based study in Taiwan.
    Br J Dermatol. 2016 Jun 7. doi: 10.1111/bjd.14789.
    PubMed     Abstract available


    May 2016
  257. GUITERA P, Menzies SW, Argenziano G, Longo C, et al
    Dermoscopy and in vivo confocal microscopy are complimentary techniques for the diagnosis of difficult amelanotic and light colored skin lesions.
    Br J Dermatol. 2016 May 13. doi: 10.1111/bjd.14749.
    PubMed     Abstract available


  258. LLOYD-LAVERY A, Hodgson T, Coupe N, Bond S, et al
    Delayed oral toxicity from long-term vemurafenib therapy.
    Br J Dermatol. 2016;174:1159-60.
    PubMed    


  259. LALLAS A, Tschandl P, Kyrgidis A, Stolz W, et al
    Dermoscopic clues to differentiate facial lentigo maligna from pigmented actinic keratosis.
    Br J Dermatol. 2016;174:1079-85.
    PubMed     Abstract available


  260. GREVELING K, de Vries K, van Doorn MB, Prens EP, et al
    A two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod: excellent cosmesis, but frequent recurrences on the nose.
    Br J Dermatol. 2016;174:1134-6.
    PubMed    


    April 2016
  261. NILSEN LT, Hannevik M, Veierod MB
    Ultraviolet exposure from indoor tanning devices: a systematic review.
    Br J Dermatol. 2016;174:730-40.
    PubMed     Abstract available


    March 2016
  262. PARTARRIEU-MEJIAS F, Perez-Velasquez F
    Image Gallery: Xeroderma pigmentosum.
    Br J Dermatol. 2016;174:e12.
    PubMed    


  263. DE VRIES K, Greveling K, Prens LM, Munte K, et al
    Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision.
    Br J Dermatol. 2016;174:588-93.
    PubMed     Abstract available


  264. BELLON T, Lerma V, Gonzalez-Valle O, Gonzalez Herrada C, et al
    Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.
    Br J Dermatol. 2016;174:621-4.
    PubMed     Abstract available


    February 2016
  265. LEE S, Duffy DL, McClenahan P, Lee KJ, et al
    Heritability of naevus patterns in an adult twin cohort from the Brisbane Twin Registry: a cross-sectional study.
    Br J Dermatol. 2016;174:356-63.
    PubMed     Abstract available


    January 2016
  266. KAI AC, Richards T, Coleman A, Mallipeddi R, et al
    Five-year recurrence rate of lentigo maligna after treatment with imiquimod.
    Br J Dermatol. 2016;174:165-8.
    PubMed     Abstract available


    August 2015
  267. CHAVEZ-BOURGEOIS M, Iglesias P, Brito J, Malvehy J, et al
    Skin cancers detected as casual findings with Reflectance Confocal Microscopy (RCM) in the assessment of melasma treatment.
    Br J Dermatol. 2015 Aug 12. doi: 10.1111/bjd.14066.
    PubMed     Abstract available


    June 2015
  268. BENATI E, Zalaudek I, Piana S, Argenziano G, et al
    In vivo detection of peripheral clefting in melanocytic lesions.
    Br J Dermatol. 2015 Jun 23. doi: 10.1111/bjd.13959.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: